Live
PharmaVoiceAstraZeneca aims for a new blockbuster run in cardio diseaseFierceBiotechServier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipelineLabiotechWhat China’s new CGT rules mean for biotech businessEndpoints NewsTurn Therapeutics' eczema drug shows rapid response in mid-stage dataEndpoints NewsServier signs $1.55B upfront deal for Edgewise's muscular dystrophy assetsFierceBiotechEntry Japan with Clarity, Execute with ConfidenceEndpoints News#ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupClinical OMICsPersonalized Cancer Vaccine Reduces Melanoma Recurrence by 49%FierceBiotechLilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclearEndpoints NewsLilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontEndpoints News#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainBioPharma Dive2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
Endpoints News Feb 26, 2026

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

Original
Body unavailable. Use the original source.